Viyash Scientific
NSE: VIYASH · Pharmaceuticals
Snapshot
Unlock Viyash Scientific's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Viyash Scientific Limited is a veterinary healthcare company that provides finished dosage formulations across therapeutic areas including nutrition, pain management, and antibiotics. The company serves livestock, poultry, and companion animal markets globally and offers specialised analytical and formulation services.
Business Model
The company generates revenue through the development and sale of veterinary pharmaceutical products and the provision of technical analytical and formulation services. It operates as a subsidiary of CA Harbor Investments, leveraging its established infrastructure to serve international markets.
- Incorporation Year:1985
Growth Outlook
Growth is driven by the expansion of its veterinary formulation portfolio and the continued demand for therapeutic solutions in the global livestock and companion animal sectors.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight regarding the manufacturing and distribution of veterinary pharmaceuticals across international jurisdictions.
- Market Competition. Intense competition within the global animal health sector may exert pressure on pricing and profit margins.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials for pharmaceutical formulations could impact operational efficiency.
- Currency Risk. As an international operator, the company is exposed to foreign exchange volatility which may affect reported financial performance.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Viyash Scientific and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,644 Cr
TTM · consolidated
NET PROFIT
₹152 Cr
TTM · consolidated
EPS
₹3.25
TTM · consolidated
RETURN ON EQUITY
12.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
17.8%
TTM · consolidated
P/E
85.2x
Q4 FY26 · consolidated
EV/EBITDA
24.4x
Q4 FY26 · consolidated
EBITDA MARGIN
19.1%
TTM · consolidated
NET PROFIT MARGIN
7.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.1x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Viyash ScientificVIYASH | 8,352 | 85.25 | 24.37 | 70.4% | 19.1% | 12.1% | 17.8% | — |
Strides Pharma Science LimitedSTAR | 8,494 | 17.39 | 10.36 | 4.9% | 22.1% | 21.4% | 23.5% | +14.3% |
Procter & Gamble Health LimitedPGHL | 8,077 | 34.81 | 23.63 | 15.6% | 33.7% | 61.2% | 77.6% | +17.1% |
Jeena SikhoJSLL | 7,569 | 32.39 | 21.10 | — | 44.7% | 47.5% | 54.5% | +6.2% |
Akums Drugs and Pharmaceuticals Ltd.AKUMS | 7,547 | 40.97 | 15.59 | 5.8% | 14.9% | 8.2% | 13.6% | +21.6% |
Sanofi India LimitedSANOFI | 7,521 | 25.35 | 15.72 | -13.0% | 27.2% | 37.2% | 48.7% | -42.1% |
As of Q4 FY26
Financials
Viyash Scientific
NSE: VIYASH · Pharmaceuticals
Snapshot
Unlock Viyash Scientific's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Viyash Scientific Limited is a veterinary healthcare company that provides finished dosage formulations across therapeutic areas including nutrition, pain management, and antibiotics. The company serves livestock, poultry, and companion animal markets globally and offers specialised analytical and formulation services.
Business Model
The company generates revenue through the development and sale of veterinary pharmaceutical products and the provision of technical analytical and formulation services. It operates as a subsidiary of CA Harbor Investments, leveraging its established infrastructure to serve international markets.
- Incorporation Year:1985
Growth Outlook
Growth is driven by the expansion of its veterinary formulation portfolio and the continued demand for therapeutic solutions in the global livestock and companion animal sectors.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight regarding the manufacturing and distribution of veterinary pharmaceuticals across international jurisdictions.
- Market Competition. Intense competition within the global animal health sector may exert pressure on pricing and profit margins.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials for pharmaceutical formulations could impact operational efficiency.
- Currency Risk. As an international operator, the company is exposed to foreign exchange volatility which may affect reported financial performance.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Viyash Scientific and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,644 Cr
TTM · consolidated
NET PROFIT
₹152 Cr
TTM · consolidated
EPS
₹3.25
TTM · consolidated
RETURN ON EQUITY
12.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
17.8%
TTM · consolidated
P/E
85.2x
Q4 FY26 · consolidated
EV/EBITDA
24.4x
Q4 FY26 · consolidated
EBITDA MARGIN
19.1%
TTM · consolidated
NET PROFIT MARGIN
7.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.1x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26